Data on Puredel's Ossulin to be presented at the San Francisco Diabetes Technology Meeting

The first public data on Ossulin™ a new oral insulin product, will be presented today at the 9^th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin™ is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited (www.cmdpharmaltd.com) and Natreon Inc., New Brunswick, NJ., developers of the proprietary delivery platform (www.natreoninc.com).

The presentation will highlight Ossulin™’s effect in rabbits, a well-established model for studying the oral absorption of compounds. Dr Marco Prosdocimi, Chief Scientific Officer for Puredel and lead author of the study commented:

“The data to be presented clearly show that Ossulin delivers insulin efficiently, resulting in blood levels higher than those observed with other oral insulin products.”

The presentation ‘Ossulin™, a novel oral insulin product: bioavailability studies in rabbits’, was co-authored by Puredel’s scientists and world-renowned metabolic disease expert and diabetes specialist Professor Antonio Tiengo, who is advising on the project.